A Second Case of Sunitinib-associated Pyoderma Gangrenosum

Area of Science:

• Dermatology
• Oncology
• Pharmacology

Background:

• Pyoderma gangrenosum is a rare, non-infectious ulcerative skin condition.
• It often co-occurs with systemic diseases like inflammatory bowel disease and hematological disorders.
• Medication-induced pyoderma gangrenosum is infrequently reported.

Observation:

• A 61-year-old patient with recurrent renal cell carcinoma developed pyoderma gangrenosum.
• The patient was treated with sunitinib, a tyrosine kinase inhibitor.
• This represents the second reported case of sunitinib-associated pyoderma gangrenosum.

Findings:

• The clinical presentation of pyoderma gangrenosum is key to diagnosis, alongside exclusion of other ulcerative causes.
• Sunitinib, a targeted cancer therapy, is rarely associated with pyoderma gangrenosum.
• The patient's condition underscores a potential adverse drug reaction.

Implications:

• This case expands the understanding of drug-induced pyoderma gangrenosum.
• It suggests that clinicians should consider sunitinib as a potential trigger in patients presenting with ulcerative skin lesions.
• Further research is warranted to elucidate the mechanisms linking sunitinib to pyoderma gangrenosum.